Trulicity Cost in Delaware 2026: Prices, Insurance, Medicaid and Legal Alternatives

What Is the Cash Price of Trulicity in Delaware in 2026?

The manufacturer list price for Trulicity sits at $931 per month across Delaware retail pharmacies in 2026, regardless of dose. Without insurance or a discount program, that figure is what most patients see at the counter. Dulaglutide is a GLP-1 receptor agonist approved by the FDA in 2014 for glycemic control in adults with type 2 diabetes and, subsequently, for cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1].

The $931 list price applies to all four pen strengths: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg. Eli Lilly does not tier pricing by dose at retail, which means patients who have been titrated to 4.5 mg pay the same monthly sticker price as those on the starting 0.75 mg dose. GoodRx and similar pharmacy discount aggregators typically return prices between $880 and $931 at Walgreens, CVS, and Rite Aid locations across Wilmington, Dover, and Newark as of early 2026.

Dulaglutide's mechanism centers on agonism at the glucagon-like peptide-1 receptor, increasing glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying [2]. The FDA prescribing label confirms the once-weekly subcutaneous dosing schedule that makes adherence more manageable than daily injectables [1].

One practical note: Delaware has no state-level drug price cap for branded GLP-1 agents, so the federal Inflation Reduction Act insulin price caps do not extend to dulaglutide. Patients relying purely on cash pay face the full list price unless they qualify for one of the programs described in the sections below.

Does Delaware Medicaid Cover Trulicity?

Delaware Medicaid covers Trulicity for type 2 diabetes, but a prior authorization (PA) is required before the claim will process. The PA criteria generally demand documented inadequate glycemic control on metformin (unless metformin is contraindicated or not tolerated) and an HbA1c above a threshold that varies by managed care organization within the Delaware Medical Assistance Program [3].

Delaware Medicaid operates through two managed care organizations, Highmark Delaware and United Healthcare Community Plan. Both follow the state's preferred drug list, which places dulaglutide in a non-preferred tier requiring PA. Prescribers must submit clinical notes, recent HbA1c values, and a list of prior diabetes medications tried. The PA approval period is typically 12 months, after which renewal documentation is required [3].

For patients who qualify, the approved Medicaid copay structure means out-of-pocket costs drop to $0-$4 per prescription depending on income band. That is a sharp contrast to the $931 cash price. The American Diabetes Association's 2024 Standards of Care in Diabetes explicitly recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, language that can support a PA submission [4].

Medicaid beneficiaries who are denied coverage at the initial PA stage have the right to request an internal appeal within 90 days and an external review through the Delaware Insurance Commissioner if the internal appeal fails. A treating physician's letter citing the REWIND trial's cardiovascular outcomes data can strengthen an appeal considerably [5].

How Does the Eli Lilly Savings Card Work in Delaware?

Eligible commercially insured patients in Delaware may use the Lilly Insulin Value Program equivalent for Trulicity, which Eli Lilly markets as the Trulicity Savings Card. Under the 2026 program terms, commercially insured patients who meet income and insurance eligibility criteria pay as little as $25 for a 1-month or 3-month supply [6].

The card does not work for patients covered by federal programs: Medicare, Medicaid, TRICARE, or any other government-funded insurance makes a patient ineligible. That exclusion affects a significant portion of Delaware's older and lower-income population, particularly the 224,000-plus Delaware residents enrolled in Medicare as of 2024 [7].

Enrollment is done online at Lilly's website or through a participating pharmacy. The pharmacist enters the BIN, PCN, and group numbers from the card at point of sale, and the discount applies automatically. There is no income verification beyond insurance status for the basic card. Delaware patients who cannot use the savings card because of Medicare enrollment may instead apply to the Lilly Cares Foundation Patient Assistance Program, which provides Trulicity at no cost to qualifying low-income patients who lack adequate prescription coverage [6].

The Federal Trade Commission has noted in prior guidance that manufacturer copay cards, while reducing patient out-of-pocket costs, do not reduce the underlying list price and may affect formulary negotiations between insurers and pharmacy benefit managers [8]. Patients should confirm with their insurer that using a copay card does not trigger a "copay accumulator" clause that prevents card payments from counting toward the annual deductible.

Which Delaware Insurance Plans Cover Trulicity?

Most major commercial insurers operating in Delaware include dulaglutide on formulary, though tier placement and prior authorization requirements differ. Highmark Blue Cross Blue Shield of Delaware places Trulicity on Tier 3 (preferred brand) for most individual and employer plans, resulting in copays that range from $60 to $100 per month after deductible without a savings card [9].

Aetna and Cigna plans sold through the Delaware Health Insurance Marketplace (ACA exchange) generally classify dulaglutide as a non-preferred brand or specialty drug, pushing monthly costs to $150-$300 before any savings program. United Healthcare's commercial plans in Delaware tier dulaglutide variably, so the specific plan document determines cost [9].

The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes and established CVD or high CV risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended independent of baseline HbA1c" [4]. That recommendation level can be used by prescribers to argue for formulary exceptions when a plan denies dulaglutide in favor of a lower-tier agent.

Employer-sponsored plans in Delaware are governed by ERISA and are not required to follow state insurance mandates, which means coverage terms vary widely. Patients with employer plans should review the Summary of Benefits and Coverage document, specifically the specialty drug cost-sharing section, before assuming coverage mirrors the state-regulated market [10].

Is Compounded Dulaglutide Legal in Delaware?

Compounded dulaglutide is legal in Delaware when prepared by a state-licensed 503A compounding pharmacy operating under section 503A of the Federal Food, Drug, and Cosmetic Act [11]. A 503A pharmacy may compound dulaglutide for an individual patient provided a licensed prescriber has issued a valid, patient-specific prescription and the compound is not a copy of a commercially available drug that is not on the FDA drug shortage list.

This is where the legal picture gets specific. Dulaglutide (Trulicity) is not currently on the FDA's official drug shortage list [12]. That status matters because FDA guidance published in 2024 clarified that 503A pharmacies may compound copies of commercially available drugs only when the commercial product is on the shortage list or when a patient has a documented allergy or clinical need that the branded product cannot address [12]. Compounding purely for cost reasons, when the branded drug is available and not in shortage, sits in a regulatory gray zone that the FDA has indicated it will scrutinize.

Practically, some Delaware 503A pharmacies do compound dulaglutide peptides sourced as active pharmaceutical ingredients. Patients and prescribers should verify that the compounding pharmacy holds a current Delaware Board of Pharmacy license and that the prescriber documents a clinical rationale in the chart beyond cost alone. The FDA's draft guidance on peptide compounding, updated in 2024, recommends that patients ask for a Certificate of Analysis confirming the API's identity and purity [12].

The HealthRX clinical team uses the following decision framework when evaluating compounded dulaglutide for Delaware patients:

1. Confirm the patient has a valid type 2 diabetes or GLP-1-indicated diagnosis documented in the chart.
2. Verify the compounding pharmacy holds an active Delaware Board of Pharmacy 503A license.
3. Request a Certificate of Analysis for the active pharmaceutical ingredient batch.
4. Document the clinical rationale (e.g., confirmed commercial product intolerance, documented insurance denial with appeal exhausted) rather than listing cost as the sole reason.
5. Schedule a follow-up HbA1c at 12 weeks to confirm therapeutic equivalence with the expected branded product response.

What Does the Clinical Evidence Say About Dulaglutide's Effectiveness?

The REWIND trial (N=9,901), published in The Lancet in 2019, remains the landmark cardiovascular outcomes study for dulaglutide. Over a median follow-up of 5.4 years, dulaglutide 1.5 mg once weekly reduced the composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death (3-point MACE) by 12% relative to placebo (HR 0.88 to 95% CI 0.79-0.99, P<0.026) [5]. That trial enrolled patients with a mean age of 66 years, 31% of whom had no prior cardiovascular event, making the population more representative of typical type 2 diabetes patients than earlier CVOT trials.

HbA1c reduction across the REWIND population averaged 0.61 percentage points more than placebo at one year [5]. Body weight fell by a mean of 1.46 kg more than placebo over the trial period, a more modest effect than seen with semaglutide, consistent with dulaglutide's position as a moderate-weight-loss GLP-1 agent rather than a dedicated obesity therapy.

The FDA approved dulaglutide's cardiovascular risk reduction indication in 2020, citing REWIND as the key evidence [1]. The prescribing label now carries indication language covering adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1].

For HbA1c lowering specifically, the AWARD trial program across eight phase 3 studies showed dulaglutide 1.5 mg reducing HbA1c by 1.1 to 1.6 percentage points from baseline across diverse populations over 26 to 52 weeks [13]. The AWARD-5 trial (N=1,098) demonstrated non-inferiority to sitagliptin 100 mg at 52 weeks, with dulaglutide 1.5 mg producing a 1.1 percentage point HbA1c reduction versus 0.39 percentage points for sitagliptin (P<0.001) [13].

Renal protection data have also accumulated. A prespecified secondary analysis of REWIND showed dulaglutide reduced the composite renal outcome (new macroalbuminuria, 40% sustained decline in eGFR, or renal replacement therapy) by 15% relative to placebo (HR 0.85 to 95% CI 0.77-0.93) [14]. The American Diabetes Association's 2024 Standards of Care cite this data in recommending GLP-1 receptor agonists for patients with type 2 diabetes and chronic kidney disease [4].

Can I Get a Trulicity Prescription via Telehealth in Delaware?

Telehealth prescribing of Trulicity is permitted in Delaware. Delaware is a member of the Interstate Medical Licensure Compact (IMLC), which allows physicians licensed in compact member states to obtain expedited licensure to practice in Delaware [15]. For existing Delaware-licensed providers, the state's telehealth statute (Title 24, Delaware Code) allows for prescription of Schedule V and non-scheduled medications, including dulaglutide, following a telehealth encounter that includes a synchronous audio-video visit establishing a patient-provider relationship [15].

The DEA's telemedicine prescribing rules, which focus on controlled substances, do not restrict non-scheduled drugs like dulaglutide, so no in-person visit is required to obtain an initial Trulicity prescription via telehealth in Delaware. HealthRX providers licensed in Delaware can prescribe dulaglutide following a video consultation that includes review of recent labs (HbA1c, renal function), medication history, and cardiovascular risk assessment.

Patients should ensure the telehealth platform they use employs a provider with active Delaware licensure. Out-of-state prescriptions written by providers not licensed in Delaware are not valid under Delaware pharmacy law [15].

What Is the Cheapest Way to Get Trulicity in Delaware?

The lowest-cost path depends on insurance status, income, and clinical circumstances.

For commercially insured patients: Use the Eli Lilly Trulicity Savings Card to reduce copay to $25 per month. Combine this with a 90-day supply dispensed through a mail-order pharmacy affiliated with your plan, which often reduces per-dose cost further [6].

For Medicaid patients: Pursue the prior authorization process. If denied, appeal with REWIND cardiovascular outcomes data and the ADA 2024 guideline recommendation. Approved Medicaid patients pay $0-$4 per fill [4].

For Medicare patients: The Medicare Part D redesign under the Inflation Reduction Act capped annual out-of-pocket drug spending at $2,000 starting in 2025, which may help patients on dulaglutide long-term [16]. Apply to the Lilly Cares Foundation Patient Assistance Program if income qualifies.

For uninsured or underinsured patients: The Lilly Cares Foundation accepts applications from patients with household incomes up to 400% of the federal poverty level. Processing typically takes 2-4 weeks. Some Delaware federally qualified health centers (FQHCs) can access 340B pricing for dulaglutide, reducing acquisition cost substantially [16].

For patients considering compounded dulaglutide: Confirm 503A pharmacy licensure and obtain a Certificate of Analysis. Understand that the FDA has signaled increased enforcement scrutiny on compounded GLP-1 peptides not tied to documented shortage or patient-specific clinical need [12].

How Does Dulaglutide Compare to Other GLP-1 Agents Available in Delaware?

Delaware patients with type 2 diabetes or obesity-related GLP-1 indications have access to several agents, each with distinct pricing and coverage profiles.

Semaglutide (Ozempic, 0.5-2 mg weekly, type 2 diabetes) carries a similar list price near $935 per month in 2026. The SUSTAIN-6 trial (N=3,297) showed semaglutide 0.5 mg and 1 mg reduced 3-point MACE by 26% versus placebo over 104 weeks (HR 0.74 to 95% CI 0.58-0.95, P<0.001 for non-inferiority, P=0.02 for superiority) [17]. Semaglutide's HbA1c reduction tends to exceed dulaglutide's by approximately 0.4-0.5 percentage points in head-to-head comparisons.

Liraglutide (Victoza, 1.2-1.8 mg daily) requires daily injection versus dulaglutide's once-weekly schedule. The LEADER trial (N=9,340) showed liraglutide reduced 3-point MACE by 13% (HR 0.87 to 95% CI 0.78-0.97, P=0.01 for superiority) [18]. Daily injection burden makes patient preference often favor weekly agents like dulaglutide.

Tirzepatide (Mounjaro, 5-15 mg weekly) acts on both GLP-1 and GIP receptors and produces greater HbA1c and weight reduction than dulaglutide. The SURPASS-2 trial (N=1,879) showed tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg (P<0.001) at 40 weeks [19]. List price is similar to dulaglutide, but tirzepatide does not yet have as broad cardiovascular outcomes evidence as dulaglutide or liraglutide.

The ADA 2024 Standards recommend selecting among GLP-1 agents based on cardiovascular and renal comorbidities, weight loss goals, injection frequency preference, and cost [4]. Dulaglutide's once-weekly pen, established CVOT data from REWIND, and broad Medicaid/commercial formulary coverage make it a clinically rational first choice for many Delaware patients with type 2 diabetes.

Understanding Dulaglutide's Side Effect Profile Before Starting

Common side effects documented in the Trulicity FDA prescribing label include nausea (12.4% vs. 5.3% placebo), diarrhea (8.9% vs. 6.7% placebo), vomiting (6.0% vs. 2.3% placebo), and abdominal pain [1]. Most gastrointestinal effects peak during dose escalation and diminish over 4-8 weeks.

The boxed warning on the Trulicity label addresses thyroid C-cell tumors observed in rodent studies at all doses tested. The clinical relevance in humans remains uncertain. Dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 [1].

Pancreatitis has been reported in clinical trials at a rate of 0.11 events per 100 patient-years with dulaglutide versus 0.06 events per 100 patient-years with placebo in REWIND [5]. Patients with a history of pancreatitis require careful risk-benefit assessment before starting dulaglutide.

Hypoglycemia risk is low when dulaglutide is used as monotherapy or with non-sulfonylurea agents. Adding dulaglutide to a sulfonylurea or insulin regimen increases hypoglycemia risk, and dose reduction of the concomitant agent may be warranted [1]. The FDA label recommends against use in patients with type 1 diabetes or for treatment of diabetic ketoacidosis [1].

Injection site reactions occur in fewer than 1% of patients in controlled trials. The autoinjector pen design, which hides the needle and automates injection, tends to reduce injection anxiety in patients new to injectable therapy [2].